AstraZeneca invests $2bn in Summit Therapeutics and expands ivonescimab cancer collaboration
AstraZeneca is investing $2bn in Summit Therapeutics alongside a clinical collaboration focused on combinations involving the PD-1/VEGF bispecific antibody ivonescimab.
The companies plan to evaluate ivonescimab with AstraZeneca oncology medicines, beginning with the antibody-drug conjugate sonesitatug vedotin.
The transaction combines a major equity investment with expanded clinical collaboration around one of the industry's closely watched PD-1/VEGF programmes.
Field | Content |
Alert Type | Deals |
Companies | AstraZeneca; Summit Therapeutics |
Deal Type | Equity investment and clinical collaboration |
Asset or Company | Ivonescimab |
Therapy Area(s) | Oncology |
Technology or Modality | PD-1/VEGF bispecific antibody |
Deal Value | $2bn equity investment |
Development Stage | Clinical development |
Geography | Global collaboration |
What Happened | AstraZeneca announced a $2bn equity investment in Summit Therapeutics alongside a clinical collaboration to evaluate combinations involving ivonescimab and AstraZeneca oncology medicines. |
Why It Matters | The agreement expands AstraZeneca's exposure to the emerging PD-1/VEGF bispecific field while creating opportunities to evaluate ivonescimab alongside assets from its established oncology portfolio. |
Supporting Context | The collaboration is expected to begin by evaluating ivonescimab in combination with AstraZeneca's antibody-drug conjugate sonesitatug vedotin. |
Strategic Rationale | AstraZeneca gains strategic exposure to Summit and an opportunity to explore combinations between ivonescimab and its own oncology pipeline. |
Potential Impact | The collaboration could generate new combination regimens involving PD-1/VEGF inhibition and AstraZeneca oncology therapies if clinical studies support their use. |
Key Takeaway | AstraZeneca is making a $2bn strategic investment in Summit while expanding clinical work around ivonescimab combination therapies. |
What to Watch | Initiation and results of combination studies involving ivonescimab and AstraZeneca oncology assets. |
Primary Source | AstraZeneca |
Relevant Date | 28 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments